Stereotaxic Irradiation of Hepatocellular Carcinoma

Stereotaxic Irradiation of Hepatocellular Carcinoma : Phase II Study

Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days for a total of 45 Gy.

Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days for a total of 45 Gy

Inclusion Criteria:

• Primitive liver cancer (hepatocellular carcinoma), proved by histology or diagnostic according to BCLC criteria
• T1-3 N0 M0
• With only one intra hepatic lesion and dimensions between 1 cm and 6 cm (IRM or hepatic scanner)
• Stereotaxic radiotherapy treatment approved in multidisciplinary consultation, the patient being rejected for standard therapeutic
• Age >= 18 ans
• Previous anti tumoral treatment allowed but suspended since at least 15 days before the inclusion
• OMS =< 2
• Portal thrombosis allowed
• Portal high blood pressure allowed
• No contraindication of fiducials implantation, hemostasis disorders must be treated before the implantation
• In case of underlying cirrhosis, only the Child-Pugh A is allowed
• Life expectancy >= 12 weeks
• Women must have an active contraception during all the study
• Patient affiliated to health insurance
• Patient must sign the consent

Exclusion Criteria:

• T4
• Cirrhosis Child B and C
• Hepatic lesion < 1 cm or > 6 cm
• 2 hepatic lesions or more
• Recurrent or metastatic disease
• Patient already included in another therapeutic trial with an experimental molecule
• Allergy to gold
• Pregnant women or susceptible to be pregnant or breastfeeding
• Unable for medical follow-up (geographic, social or mental reasons)